Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486515 | 0.95 | ALDH1A1 (0.62) | SLC6A3SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL6190342 | 0.86 | SIGMAR1 (0.69) | SIGMAR1ALDH1A1 | |
| SCHEMBL7753404 | 0.84 | ALDH1A1 (0.62) | SIGMAR1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL27138554 | 0.82 | MEN1 (0.64) | SLC6A3SIGMAR1MEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL9222207 | 0.82 | SLC6A3 (0.84) | SLC6A3SIGMAR1HTR1ADRD2 | |
| SCHEMBL9597186 | 0.82 | SLC6A3 (0.91) | SLC6A3SIGMAR1HTR1ADRD2 | |
| SCHEMBL21418234 | 0.80 | ALDH1A1 (0.60) | SIGMAR1ALDH1A1KMT2AKCNH2POLB | |
| SCHEMBL5524549 | 0.80 | MEN1 (0.69) | SLC6A3SIGMAR1MEN1KMT2AKCNH2 | |
| 1-Phenethylpiperidine SCHEMBL466935 | 0.79 | SIGMAR1 (0.82) | SLC6A3SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL3158860 | 0.79 | ALDH1A1 (0.68) | SIGMAR1ALDH1A1KMT2AKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | SLC6A3 460/4885SIGMAR1 218/4885ALDH1A1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.